Polmonite interstiziale fibrosante da amiodarone

Bartalena L, Bogazzi F, Chiovato L et al. (2018) European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J 7(2):55–66 Cappellani D, Bogazzi F (2019) Gestione clinica della tireopatia da amiodarone. Endocrinologo 20(Suppl 1):46 Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322 Gao S, Dai W, Zhang L et al. (2013) Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease and acute liver injury: dronedarone versus amiodarone and other antiarrthythmics. J Atr Fibrillation 6(4):890 Schwaiblmair M, Berghaus T, Haeckel T et al. (2010) Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 99:693–700 Wolkove N, Baltzan M (2009) Amiodarone pulmonary toxicity. Can Respir J 16:43–48 Yamada Y, Shiga T, Matsuda N et al. (2007) Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 71:1610–1616 Stewart JJ, Chawla R (2008) Amiodarone pneumonitis. Respir Care 53:370–375 Mankikian J, Favelle O, Guillon A et al. (2014) Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med 108:638–646 Light RW, Lee G (2016) Pleural diseases, 3rd edn. CRC Press, Boca Raton, p 387